# A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

> **NCT04947033** · PHASE1 · UNKNOWN · sponsor: **I-Mab Biopharma US Limited** · enrollment: 25 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TJ210001 Injection

## Key facts

- **NCT ID:** NCT04947033
- **Lead sponsor:** I-Mab Biopharma US Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04947033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04947033, "A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04947033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*